Current Challenges in Chronic Bronchial Infection in Patients with Chronic Obstructive Pulmonary Disease
暂无分享,去创建一个
M. Miravitlles | M. Martínez-García | J. López-Campos | R. Cantón | J. Soler-Cataluña | David de la Rosa Carrillo
[1] D. Graziani,et al. Clinical Management of COPD in a Real-World Setting. A Big Data Analysis , 2021 .
[2] M. Martínez-García,et al. Consensus Document on the Diagnosis and Treatment of Chronic Bronchial Infection in Chronic Obstructive Pulmonary Disease. , 2020, Archivos de bronconeumologia.
[3] J. Curtis,et al. Blood Eosinophil Counts in Clinical Trials for Chronic Obstructive Pulmonary Disease , 2020, American journal of respiratory and critical care medicine.
[4] D. Graziani,et al. Clinical Management of COPD in a Real-World Setting. A Big Data Analysis. , 2020 .
[5] A. Agustí,et al. BRONCHIAL INFECTION AND temporal evolution OF bronchiectasis in patients with chronic obstructive pulmonary disease. , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[6] S. Johnston,et al. LONG TERM IMPACT OF INHALED CORTICOSTEROID USE IN ASTHMA AND COPD: REVIEW OF MECHANISMS THAT UNDERLIE RISKS. , 2020, The Journal of allergy and clinical immunology.
[7] A. Agustí,et al. Inhaled Steroids, Circulating Eosinophils, Chronic Airway Infection and Pneumonia Risk in Chronic Obstructive Pulmonary Disease: A Network Analysis. , 2020, American journal of respiratory and critical care medicine.
[8] H. Ochs-Balcom,et al. Impact of Pseudomonas aeruginosa Isolation on Mortality and Outcomes in an Outpatient Chronic Obstructive Pulmonary Disease Cohort , 2020, Open forum infectious diseases.
[9] M. Miravitlles,et al. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2019 Report: Future Challenges. , 2020, Archivos de Bronconeumologia.
[10] R. Dessau,et al. Pseudomonas aeruginosa and risk of death and exacerbations in patients with chronic obstructive pulmonary disease: an observational cohort study of 22.053 patients. , 2020, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.
[11] D. Bouros,et al. Low penetrance of antibiotics in the epithelial lining fluid. Experience from the use of inhaled antibiotics in patients with non CF-bronchiectasis. , 2019, Pulmonary pharmacology & therapeutics.
[12] Yuejun Du,et al. Inhaled corticosteroids and risk of pneumonia in patients with chronic obstructive pulmonary disease: A meta-analysis of randomized controlled trials. , 2019, International immunopharmacology.
[13] G. Verleden,et al. Azithromycin during Acute COPD Exacerbations Requiring Hospitalization (BACE): a Multicentre, Randomized, Double-blind, Placebo-controlled Trial. , 2019, American journal of respiratory and critical care medicine.
[14] C. Montón,et al. Nebulized Colistin And Continuous Cyclic Azithromycin In Severe COPD Patients With Chronic Bronchial Infection Due To Pseudomonas aeruginosa: A Retrospective Cohort Study , 2019, International journal of chronic obstructive pulmonary disease.
[15] Thomas B. Clarke,et al. Inhaled corticosteroid suppression of cathelicidin drives dysbiosis and bacterial infection in chronic obstructive pulmonary disease , 2019, Science Translational Medicine.
[16] C. Daley,et al. Comparative risks of chronic inhaled corticosteroids and macrolides for bronchiectasis , 2019, European Respiratory Journal.
[17] X. Yao,et al. Effects of long-term macrolide therapy at low doses in stable COPD , 2019, International journal of chronic obstructive pulmonary disease.
[18] Meilan K. Han,et al. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease: the GOLD science committee report 2019 , 2019, European Respiratory Journal.
[19] G. Verleden,et al. AZITHROMYCIN DURING ACUTE CHRONIC OBSTRUCTIVE PULMONARY DISEASE EXACERBATIONS REQUIRING , 2019 .
[20] M. Tunney,et al. British Thoracic Society Guideline for bronchiectasis in adults , 2018, Thorax.
[21] M. Vitacca,et al. Bacterial Colonization in COPD Patients Admitted to a Rehabilitation Respiratory Unit and Impact on Length of Stay: A Real-Life Study , 2018, COPD.
[22] Yan Chen,et al. Long-term macrolide treatment for the prevention of acute exacerbations in COPD: a systematic review and meta-analysis , 2018, International journal of chronic obstructive pulmonary disease.
[23] H. Mukae,et al. The microbiome in the lower respiratory tract. , 2018, Respiratory investigation.
[24] A. Anzueto,et al. Chronic Obstructive Pulmonary Disease Exacerbations: A Need for Action. , 2018, The American journal of medicine.
[25] C. Strange,et al. Inhaled corticosteroids for chronic obstructive pulmonary disease: what is their role in therapy? , 2018, International journal of chronic obstructive pulmonary disease.
[26] M. Martínez-García,et al. Current and future pharmacotherapy options for non-cystic fibrosis bronchiectasis , 2018, Expert review of respiratory medicine.
[27] S. Johnston,et al. Corticosteroid suppression of antiviral immunity increases bacterial loads and mucus production in COPD exacerbations , 2018, Nature Communications.
[28] C. Morin,et al. The Efficacy of MAG-DHA for Correcting AA/DHA Imbalance of Cystic Fibrosis Patients , 2018, Marine drugs.
[29] James R. Brown,et al. Longitudinal profiling of the lung microbiome in the AERIS study demonstrates repeatability of bacterial and eosinophilic COPD exacerbations , 2018, Thorax.
[30] C. Olveira,et al. Spanish Guidelines on Treatment of Bronchiectasis in Adults. , 2017, Archivos de bronconeumologia.
[31] James R. Brown,et al. Sputum microbiome temporal variability and dysbiosis in chronic obstructive pulmonary disease exacerbations: an analysis of the COPDMAP study , 2017, Thorax.
[32] C. Olveira,et al. Spanish Guidelines on the Evaluation and Diagnosis of Bronchiectasis in Adults , 2017 .
[33] R. Cantón,et al. Normativa sobre el tratamiento de las bronquiectasias en el adulto , 2017 .
[34] J. Raduà,et al. Effectiveness of treatment with nebulized colistin in patients with COPD , 2017, International journal of chronic obstructive pulmonary disease.
[35] A. Spanevello,et al. Long-term effects of inhaled corticosteroids on sputum bacterial and viral loads in COPD , 2017, European Respiratory Journal.
[36] T. Welte,et al. European Respiratory Society guidelines for the management of adult bronchiectasis , 2017, European Respiratory Journal.
[37] J. Kwong,et al. The risk of mycobacterial infections associated with inhaled corticosteroid use , 2017, European Respiratory Journal.
[38] J. Soriano,et al. Spanish Guidelines for Management of Chronic Obstructive Pulmonary Disease (GesEPOC) 2017. Pharmacological Treatment of Stable Phase. , 2017, Archivos de bronconeumologia.
[39] M. Miravitlles,et al. Bronchiectasis in COPD patients: more than a comorbidity? , 2017, International journal of chronic obstructive pulmonary disease.
[40] M. Davoli,et al. Inhaled Corticosteroid Use in Chronic Obstructive Pulmonary Disease and Risk of Pneumonia: A Nested Case-Control Population-based Study in Lazio (Italy)—The OUTPUL Study , 2017, COPD.
[41] Philip M. Hansbro,et al. INVITED REVIEW SERIES: UNRAVELLING THE MANY FACES OF COPD TO OPTIMIZE ITS CARE AND OUTCOMES , 2017 .
[42] Wouter A. A. de Steenhuijsen Piters,et al. The microbiota of the respiratory tract: gatekeeper to respiratory health , 2017, Nature Reviews Microbiology.
[43] John R. Hurst,et al. Management of COPD exacerbations: a European Respiratory Society/American Thoracic Society guideline , 2017, European Respiratory Journal.
[44] É. Rousseau,et al. Novel n-3 PUFA monoacylglycerides of pharmacological and medicinal interest: Anti-inflammatory and anti-proliferative effects. , 2016, European journal of pharmacology.
[45] O. Sibila,et al. Pseudomonas aeruginosa resistance patterns and clinical outcomes in hospitalized exacerbations of COPD , 2016, Respirology.
[46] M. Tunney,et al. The role of anaerobic bacteria in the cystic fibrosis airway , 2016, Current opinion in pulmonary medicine.
[47] Y. Kong,et al. Effect of Fluoroquinolones and Macrolides on Eradication and Resistance of Haemophilus influenzae in Chronic Obstructive Pulmonary Disease , 2016, Antimicrobial Agents and Chemotherapy.
[48] M. Miravitlles,et al. Treatment of patients with COPD and recurrent exacerbations: the role of infection and inflammation , 2016, International journal of chronic obstructive pulmonary disease.
[49] J. van der Palen,et al. Safety and Tolerability of Nebulized Amoxicillin-Clavulanic Acid in Patients with COPD (STONAC 1 and STONAC 2) , 2016, COPD.
[50] T. Welte,et al. Report of the European Respiratory Society/European Cystic Fibrosis Society task force on the care of adults with cystic fibrosis , 2015, European Respiratory Journal.
[51] É. Rousseau,et al. Reversal of IL-13-induced inflammation and Ca(2+) sensitivity by resolvin and MAG-DHA in association with ASA in human bronchi. , 2015, Prostaglandins & other lipid mediators.
[52] M. Greenstone,et al. Prolonged antibiotics for non-cystic fibrosis bronchiectasis in children and adults. , 2015, The Cochrane database of systematic reviews.
[53] J. Wedzicha,et al. Effects of different antibiotic classes on airway bacteria in stable COPD using culture and molecular techniques: a randomised controlled trial , 2015, Thorax.
[54] I. Pavord,et al. Airway bacteria measured by quantitative polymerase chain reaction and culture in patients with stable COPD: relationship with neutrophilic airway inflammation, exacerbation frequency, and lung function , 2015, International journal of chronic obstructive pulmonary disease.
[55] A. Anzueto,et al. Antibiotic prophylaxis in COPD: Why, when, and for whom? , 2015, Pulmonary pharmacology & therapeutics.
[56] Yahong Chen,et al. Bacterial Infection, Airway and Systemic Inflammation and Clinical Outcomes before and after Treatment of AECOPD, a Longitudinal and Cross-sectional Study , 2015, COPD.
[57] M. Polkey,et al. Does a single Pseudomonas aeruginosa isolation predict COPD mortality? , 2014, European Respiratory Journal.
[58] C. Montón,et al. Pseudomonas aeruginosa isolates in severe chronic obstructive pulmonary disease: characterization and risk factors , 2014, BMC Pulmonary Medicine.
[59] H. Hoogsteden,et al. Azithromycin maintenance treatment in patients with frequent exacerbations of chronic obstructive pulmonary disease (COLUMBUS): a randomised, double-blind, placebo-controlled trial. , 2014, The Lancet. Respiratory medicine.
[60] J. Wedzicha,et al. Human rhinovirus infection during naturally occurring COPD exacerbations , 2014, European Respiratory Journal.
[61] A. Anzueto,et al. Antibiotics for treatment and prevention of exacerbations of chronic obstructive pulmonary disease. , 2013, The Journal of infection.
[62] P. Poole,et al. Prophylactic antibiotic therapy for chronic obstructive pulmonary disease (COPD). , 2013, The Cochrane database of systematic reviews.
[63] Antonio Anzueto,et al. Antibiotics for acute and chronic respiratory infection in patients with chronic obstructive pulmonary disease. , 2013, American journal of respiratory and critical care medicine.
[64] S. Nambiar,et al. Cardiovascular risks with azithromycin. , 2013, The New England journal of medicine.
[65] E. Brass. Cardiovascular risks with azithromycin. , 2013, The New England journal of medicine.
[66] C. Olveira,et al. Inhaled antibiotics for the treatment of chronic bronchopulmonary Pseudomonas aeruginosa infection in cystic fibrosis: systematic review of randomised controlled trials , 2013, Expert opinion on pharmacotherapy.
[67] J. Alexander,et al. Cardiovascular risks with azithromycin and other antibacterial drugs. , 2013, The New England journal of medicine.
[68] G. Rogers,et al. Clinical measures of disease in adult non-CF bronchiectasis correlate with airway microbiota composition , 2013, Thorax.
[69] M. Miravitlles,et al. Chronic bronchial infection in COPD. Is there an infective phenotype? , 2012, Respiratory Medicine.
[70] J. Maurer. Acute Exacerbations of Chronic Obstructive Pulmonary Disease: Identification of Biologic Clusters and Their Biomarkers , 2012 .
[71] A. Anzueto,et al. Moxifloxacin versus amoxicillin/clavulanic acid in outpatient acute exacerbations of COPD: MAESTRAL results , 2011, European Respiratory Journal.
[72] M. Miravitlles,et al. Sputum colour and bacteria in chronic bronchitis exacerbations: a pooled analysis , 2011, European Respiratory Journal.
[73] M. Rodríguez-Carballeira,et al. Pseudomonas aeruginosa and Mortality after Hospital Admission for Chronic Obstructive Pulmonary Disease , 2011, Respiration.
[74] Christopher E Brightling,et al. Acute exacerbations of chronic obstructive pulmonary disease: identification of biologic clusters and their biomarkers. , 2011, American journal of respiratory and critical care medicine.
[75] C. Montón,et al. International Journal of Copd Dovepress Long-term Azithromycin Therapy in Patients with Severe Copd and Repeated Exacerbations , 2022 .
[76] John Connett,et al. Azithromycin for prevention of exacerbations of COPD. , 2011, The New England journal of medicine.
[77] S. Johnston,et al. Experimental rhinovirus infection as a human model of chronic obstructive pulmonary disease exacerbation. , 2011, American journal of respiratory and critical care medicine.
[78] T. Seemungal,et al. Reported pneumonia in patients with COPD: findings from the INSPIRE study. , 2011, Chest.
[79] R. Cantón,et al. Infección bronquial crónica: el problema de Pseudomonas aeruginosa , 2011 .
[80] J. DiNicolantonio,et al. Azithromycin for prevention of exacerbations of COPD. , 2011, The New England journal of medicine.
[81] R. del Campo,et al. [Chronic bronchial infection: the problem of Pseudomonas aeruginosa]. , 2011, Archivos de bronconeumologia.
[82] W. MacNee,et al. Effect of 6 Months of Erythromycin Treatment on Inflammatory Cells in Induced Sputum and Exacerbations in Chronic Obstructive Pulmonary Disease , 2010, Respiration.
[83] R. Cosentini,et al. Prophylactic antibiotic therapy in chronic obstructive pulmonary disease , 2010, Therapeutic advances in respiratory disease.
[84] F. Blasi,et al. Long-term azithromycin use in patients with chronic obstructive pulmonary disease and tracheostomy. , 2010, Pulmonary pharmacology & therapeutics.
[85] M. Miravitlles,et al. Colour of sputum is a marker for bacterial colonisation in chronic obstructive pulmonary disease , 2010, Respiratory research.
[86] J. Wedzicha,et al. Pulsed moxifloxacin for the prevention of exacerbations of chronic obstructive pulmonary disease: a randomized controlled trial , 2010, Respiratory research.
[87] Pradeep K. Singh,et al. Azithromycin maintains airway epithelial integrity during Pseudomonas aeruginosa infection. , 2010, American Journal of Respiratory Cell and Molecular Biology.
[88] B. Tümmler,et al. Pseudomonas aeruginosa population biology in chronic obstructive pulmonary disease. , 2009, The Journal of infectious diseases.
[89] M. Sala,et al. Effectiveness and safety of colistin for the treatment of multidrug-resistant Pseudomonas aeruginosa infections , 2009, Infection.
[90] M. Rodríguez-Carballeira,et al. Pseudomonas aeruginosa in patients hospitalised for COPD exacerbation: a prospective study , 2009, European Respiratory Journal.
[91] T. Murphy. Pseudomonas aeruginosa in adults with chronic obstructive pulmonary disease , 2009, Current opinion in pulmonary medicine.
[92] M. Salvadó,et al. Mortality of COPD Patients Infected with Multi-Resistant Pseudomonas aeruginosa: A Case and Control Study , 2009, Infection.
[93] M. Maciá,et al. Chronic Pseudomonas aeruginosa infection in chronic obstructive pulmonary disease. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[94] T. Seemungal,et al. Long-term erythromycin therapy is associated with decreased chronic obstructive pulmonary disease exacerbations. , 2008, American journal of respiratory and critical care medicine.
[95] R. Negro,et al. Tobramycin Nebulizer Solution in severe COPD patients colonized with Pseudomonas aeruginosa: effects on bronchial Inflammation , 2008, Advances in therapy.
[96] T. Murphy,et al. Pseudomonas aeruginosa in chronic obstructive pulmonary disease. , 2008, American journal of respiratory and critical care medicine.
[97] S. Johnston,et al. Rhinovirus exposure impairs immune responses to bacterial products in human alveolar macrophages , 2008, Thorax.
[98] M. Niederman,et al. A Prediction Model for Bacterial Etiology in Acute Exacerbations of COPD , 2007, Infection.
[99] S. Sethi,et al. Airway inflammation and bronchial bacterial colonization in chronic obstructive pulmonary disease. , 2006, American journal of respiratory and critical care medicine.
[100] A. Oliver,et al. Antimicrobial therapy for pulmonary pathogenic colonisation and infection by Pseudomonas aeruginosa in cystic fibrosis patients. , 2005, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.
[101] A. Torres,et al. Microbiologic determinants of exacerbation in chronic obstructive pulmonary disease. , 2005, Archives of internal medicine.
[102] H. Lode,et al. Levofloxacin versus clarithromycin in COPD exacerbation: focus on exacerbation-free interval , 2004, European Respiratory Journal.
[103] M. Pouladi,et al. Impact of cigarette smoke on clearance and inflammation after Pseudomonas aeruginosa infection. , 2004, American journal of respiratory and critical care medicine.
[104] B. Grant,et al. Strain-specific immune response to Haemophilus influenzae in chronic obstructive pulmonary disease. , 2004, American journal of respiratory and critical care medicine.
[105] P. Poole,et al. Prophylactic antibiotic therapy for chronic bronchitis. , 2013, The Cochrane database of systematic reviews.
[106] M. Miravitlles. Exacerbations of chronic obstructive pulmonary disease: when are bacteria important? , 2002, European Respiratory Journal.
[107] M. Yamaya,et al. Erythromycin and common cold in COPD. , 2001, Chest.
[108] T. Pelliniemi,et al. Trimethoprim prophylaxis of acute exacerbations in chronic obstructive pulmonary diseases. , 2009, Acta medica Scandinavica.
[109] D. Smith,et al. Five-year winter chemoprophylaxis for chronic bronchitis , 1969, British medical journal.
[110] P. Bergstein,et al. Continuous suppressive antimicrobial treatment in chronic infected bronchitis during the winter months. , 1967, Diseases of the chest.
[111] H. C. Couch. Value of chemoprophylaxis and chemotherapy in early chronic bronchitis. A report to the Medical Research Council by their working party on trials of chemotherapy in early chronic bronchitis. , 1966, British medical journal.
[112] P. Stradling,et al. A trial of continuous winter chemotherapy in chronic bronchitis. , 1960, Lancet.
[113] C. Spicer,et al. Chemotherapy in Chronic Bronchitis , 1960 .
[114] W. Leckie,et al. Evaluation of Continuous Antibiotic Therapy in Chronic Bronchitis , 1959, British medical journal.
[115] E. Moyes,et al. Long-continued treatment with tetracycline and prednisolone in chronic bronchitis; a controlled trial. , 1957, Lancet.